vTv Therapeutics
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3980 Premier Dr Ste 310, High Point, Nor...Phone Number
(336) 841-0300Website
www.vtvtherapeutics.comRevenue
$36.8 MillionStock Symbol
VTVTIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders. The company is based in High Point, North Carolina.Explore more
vTv Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is vTv Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on vTv Therapeutics recently announced quarterly report
Check if vTv Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if vTv Therapeutics is spiking on competitors!
Click to see if vTv Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once vTv Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when vTv Therapeutics launches new products
vTv Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at vTv Therapeutics
Recommended Actions
Find VP level buyers at vTv Therapeutics
Find 3 more new buyers
Compare Similar Companies to vTv Therapeutics
Compare insights from companies similar to vTv Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
vTv Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
vTv Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about vTv Therapeutics.
vTv Therapeutics financials insights
Gather financial insights about vTv Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$25M
2017
Other Financing Round
$10M
2018
Debt
$10M
2019
Multiple Rounds
$13.5M
2020
Share Placement
$47M
2022
Corporate Investment
$10M
2025
Debt
$80M
vTv Therapeutics Tech Stack
A closer look at the technologies used by vTv Therapeutics
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
vTv Therapeutics News & Media
cAMPfield Launches With $180 Million Series A to Advance Prifemilast, a Potential Best-in-Class Oral Therapy for IBD
Oral PDE4 inhibitors have demonstrated efficacy in Phase 2 studies of ulcerative colitis cAMPfield's lead candidate is prifemilast, a potentially best-in-class PDE4 inhibitor for the treatment of IBD, in-licensed from Newsoara Biopharma Co., Ltd. (Newsoara) Founded by Mountainfield...vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 39,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rul
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding vTv Therapeutics
Sign Up For FreeTo access detailed company insights
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of infla... Read More
